# New company ("NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.

*biotech · news · 2026-05-11 · The Manila Times*

## Key points

- Nxera co-founded NewCo to advance a GPCR-targeted program discovered via NxWave™ technology.
- Nxera is eligible for up to US$275 million in milestone payments and retains tiered royalties.
- Nxera retains commercial rights in Japan and certain Asia-Pacific territories for the GPCR program.
- This is Nxera’s second asset spin-out, following a model previously validated by Orexia Therapeutics.

**Companies:** Nxera Pharma Co., Ltd., NewCo
**Countries:** Japan, UK, Switzerland, South Korea

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/11/tmt-newswire/globenewswire/nxera-pharma-announces-progress-of-out-licensing-of-gpcr-targeted-program-and-participation-in-series-a-financing/2340376)

---

Canonical: https://newsio.io/n/4c9deacd-b330-4b14-bd3e-e95355e96817/new-company-newco-co-founded-by-nxera-with-a-syndicate-of-leading-healthcare-and
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works